Semaglutide
Also called Ozempic, Wegovy, Rybelsus, NN9535
Educational only, not medical advice. Dosaly reports what has been studied; it isn't a recommendation to use Semaglutide or any amount of it. Talk to a clinician.
Approved by the FDA and EMA as a prescription medicine (Ozempic and Rybelsus for type 2 diabetes; Wegovy for weight management, with a US indication for cardiovascular risk reduction).
Research applications
- Type 2 diabetes (large randomized trials)
- Obesity (large randomized trials)
- Cardiovascular outcomes (large randomized trials)
- Insulin, glucagon, stomach emptying and appetite (GLP-1 receptor)
What studies have looked at, not proven uses.
What it is
Semaglutide is a lab-made version of GLP-1, a gut hormone that affects blood sugar and appetite. It's one of the most studied peptides and an approved medicine for type 2 diabetes and weight management.
More detail
Semaglutide is a modified version of GLP-1 (glucagon-like peptide-1), a gut hormone released after meals. Changes to its amino acids and an attached fatty-acid chain let it bind albumin in the blood, giving it a half-life of about a week. Like natural GLP-1, it increases insulin release when blood glucose is high, lowers glucagon, slows stomach emptying and acts on appetite centres in the brain. It is one of the most heavily studied peptides: large randomized trials have covered type 2 diabetes, obesity, cardiovascular outcomes and other conditions, and it exists as an injection and a tablet. Gastrointestinal side effects are the most commonly reported.
Evidence listed here
- 3 human studies
Results from cells and animals often don't carry over to people. How to read peptide research
Molecular info
- Class
- Lipidated peptide (GLP-1 analog)
- Length
- 31 amino acids
- Sequence
- H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys*-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
- Research areas
- Metabolic, Weight, Cardiovascular
Lys* carries a fatty-acid chain (C18 diacid) that binds albumin; Aib at position 2 resists breakdown.
Research
- Human studyN Engl J Med · 2023Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Randomized cardiovascular outcomes trial (SELECT) in obesity without diabetes.
- Human studyN Engl J Med · 2021Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Randomized phase 3 trial (STEP 1) in adults with overweight or obesity.
- Human studyN Engl J Med · 2016Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Randomized cardiovascular outcomes trial (SUSTAIN-6) in type 2 diabetes.